This facility offers an integrated approach, housing the entire supply chain, from the production of drug substances from mammalian cells to their transformation into drug products and final packaging, in a single location. The new site’s seamless integration of research and industrial production capabilities aims to enable more efficient transitions from development to manufacturing.

 

The Center’s capability will support the production of small and large batches, and both experimental and approved drugs to facilitate a seamless transition from clinical trials to commercial manufacturing. The new center will enhance Chiesi’s focus areas in respiratory, special care treatments, and rare diseases.

 

The Biotech Center of Excellence also aims to help address healthcare challenges, aiming for a more resilient and sustainable system. Chiesi seeks to align with recent biopharmaceutical advancements and increase production in Europe, attracting international talent and investment and creating global partnerships. This project supports Chiesi’s growth in R&D, with over 20% of turnover allocated to it.

 

“At Chiesi, innovation is at the heart of everything we do. The opening of our new Biotech Center marks a bold leap forward in our commitment to delivering groundbreaking therapies that truly transform patients’ lives,” said Giuseppe Accogli, CEO at Chiesi. “This center will elevate our production capabilities to new heights and reinforce our dedication to driving innovation. More than that, it will empower us to forge powerful collaborations and push the boundaries of what’s possible in patient’s care.”

 

Of the approximately €400 million that Chiesi will invest, €120 million is allocated to infrastructure, while €260 million will be spent over the long term (2023–2030) on materials, innovative technologies, skills development, and training.

 

The Center of Excellence will employ up to 200 specialists, with current technical activities involving 60 people, expected to grow to over 80 by the end of 2025.